These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31430297)

  • 21. Evaluation of adjuvanted pandemic H1N1(2009) influenza vaccine after one and two doses in young children.
    Scheifele DW; Ward BJ; Dionne M; Vanderkooi O; Langley JM; Dobson S; Li Y; Law B; Halperin SA;
    Pediatr Infect Dis J; 2011 May; 30(5):402-7. PubMed ID: 21178654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials.
    Peeters M; Regner S; Vaman T; Devaster JM; Rombo L
    Vaccine; 2012 Oct; 30(45):6483-91. PubMed ID: 22885014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protective efficacy against pandemic influenza of seasonal influenza vaccination in children in Hong Kong: a randomized controlled trial.
    Cowling BJ; Ng S; Ma ES; Fang VJ; So HC; Wai W; Cheng CK; Wong JY; Chan KH; Ip DK; Chiu SS; Peiris JS; Leung GM
    Clin Infect Dis; 2012 Sep; 55(5):695-702. PubMed ID: 22670050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrated analysis of microRNA-mRNA expression in A549 cells infected with influenza A viruses (IAVs) from different host species.
    Gao J; Gao L; Li R; Lai Z; Zhang Z; Fan X
    Virus Res; 2019 Apr; 263():34-46. PubMed ID: 30605755
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
    Lei H; Peng X; Jiao H; Zhao D; Ouyang J
    Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
    Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
    Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
    Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M
    Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of pandemic H1N1 vaccine against influenza-related hospitalization in children.
    Gilca R; Deceuninck G; De Serres G; Boulianne N; Sauvageau C; Quach C; Boucher FD; Skowronski DM
    Pediatrics; 2011 Nov; 128(5):e1084-91. PubMed ID: 21987710
    [TBL] [Abstract][Full Text] [Related]  

  • 29. H1N1 viral proteome peptide microarray predicts individuals at risk for H1N1 infection and segregates infection versus Pandemrix(®) vaccination.
    Ambati A; Valentini D; Montomoli E; Lapini G; Biuso F; Wenschuh H; Magalhaes I; Maeurer M
    Immunology; 2015 Jul; 145(3):357-66. PubMed ID: 25639813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pandemic influenza A(H1N1)pdm09 improves vaccination routine in subsequent years: a cohort study from 2009 to 2011.
    Tacken MA; Jansen B; Mulder J; Visscher S; Heijnen ML; Campbell SM; Braspenning JC
    Vaccine; 2013 Jan; 31(6):900-5. PubMed ID: 23246546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA-Based Attenuation of Influenza Virus across Susceptible Hosts.
    Waring BM; Sjaastad LE; Fiege JK; Fay EJ; Reyes I; Moriarity B; Langlois RA
    J Virol; 2018 Jan; 92(2):. PubMed ID: 29093096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children.
    Gilca V; De Serres G; Hamelin ME; Boivin G; Ouakki M; Boulianne N; Sauvageau C; Dionne M; Gilca R; Skowronski D
    Vaccine; 2011 Dec; 30(1):35-41. PubMed ID: 22063386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial.
    Wu J; Liu SZ; Dong SS; Dong XP; Zhang WL; Lu M; Li CG; Zhou JC; Fang HH; Liu Y; Liu LY; Qiu YZ; Gao Q; Zhang XM; Chen JT; Zhong X; Yin WD; Feng ZJ
    Vaccine; 2010 Aug; 28(38):6221-7. PubMed ID: 20638454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Uptake and effectiveness of monovalent influenza A (H1N1) pandemic 2009 vaccine among healthcare personnel in Kenya, 2010.
    Njuguna H; Ahmed J; Oria PA; Arunga G; Williamson J; Kosgey A; Muthoka P; Mott JA; Breiman RF; Katz MA
    Vaccine; 2013 Sep; 31(41):4662-7. PubMed ID: 23859843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Seasonal influenza vaccination status among children with laboratory evidence of pandemic H1N1 infection.
    Nelson CA; France EK; Shetterly SM; Glanz JM
    Pediatr Infect Dis J; 2011 Jul; 30(7):562-5. PubMed ID: 21248657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine.
    Tete SM; Jul-Larsen Å; Rostami S; Lunde THF; Søland H; Krammer F; Cox RJ
    Vaccine; 2018 Apr; 36(16):2213-2219. PubMed ID: 29548607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children.
    Knuf M; Leroux-Roels G; Rümke H; Rivera L; Pedotti P; Arora AK; Lattanzi M; Kieninger D; Cioppa GD
    Hum Vaccin Immunother; 2015; 11(2):358-76. PubMed ID: 25621884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early post-transplant vaccination with pandemic influenza A/H1N1 vaccine in pediatric heart transplant recipients.
    Altamirano-Diaz L; West L; Humar A; Ely L; Urschel S; Gubbay J; Crowcroft N; Kumar D
    Pediatr Transplant; 2011 Mar; 15(2):172-5. PubMed ID: 21176017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults.
    Hakim H; Allison KJ; Van De Velde LA; Li Y; Flynn PM; McCullers JA
    Vaccine; 2012 Jan; 30(5):879-85. PubMed ID: 22155630
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial.
    Vajo Z; Tamas F; Sinka L; Jankovics I
    Lancet; 2010 Jan; 375(9708):49-55. PubMed ID: 20018367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.